BAGSVAERD, Denmark — A lot has been happening at Swiss drug maker Novartis in the realm of vaccines.
In July, the company began early shipment of its flu vaccine, Fluvirin, in order to ensure that patients can receive the earliest possible protection against influenza. The drug maker plans to ship more than 30 million doses.
In June, the Food and Drug Administration accepted Novartis’ regulatory approval application for expanding the use of Menveo (meningococcal [Groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine) to include infants and toddlers from the age of 2 months; the vaccine is approved for individuals ages 2 years to 55 years.
Also in June, Novartis announced results from a trial of Bexsero among 1,800 infants showing that it induces a “robust immune response” to meningococcal serogroup B when administered with other routine vaccines. Meningococcal serogroup B infection can be fatal among infants in their first year.